Enjoy complimentary customisation on priority with our Enterprise License!
The doxorubicin market is estimated to grow at a CAGR of 6.07% between 2022 and 2027. The size of the market is forecasted to increase by USD 469.97 million. The growth of the market depends on several factors, including the growing prevalence of cancer cases, increasing product launches, and advancements in diagnostic methods.
This report extensively covers market segmentation by formulation (lyophilized powder and doxorubicin injection), end-user (hospital pharmacy, retail pharmacy, online pharmacy, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download Report Sample
The growing prevalence of cancer cases is notably driving the market growth, although factors such as late diagnosis and poor survival rates of patients with cancer may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Doxorubicin Market Driver
Some of the common types of cancers prevalent in the US are breast, cervical, and prostate cancers.
Risk factors such as diabetes, obesity, and related non-alcoholic fatty liver disease are associated with cancer.
Significant Doxorubicin Market Trend
Major Doxorubicin Market Challenge
According to the National Health Service (NHS), almost 50% of cancer patients in the UK are diagnosed at late stages, when it becomes difficult to control tumor growth.
The delay in diagnosis of cancer occurs at the patient, primary care, and secondary care levels.
During the late stages, the treatment of cancer using drug therapies becomes difficult, and surgery is often performed.
Hence, the late diagnosis and the poor survival rate associated with cancer limit the use of doxorubicin for the treatment of cancer and increase the mortality rates associated with cancer.
Key Doxorubicin Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Doxorubicin Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Baxter International Inc. - The company offers doxorubicin such as Doxorubicin HCl liposome injection.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the lyophilized powder segment will be significant during the forecast period. Lyophilization is a process wherein water is removed from a product after being frozen and placed under a vacuum, which allows ice to convert directly from solid to vapor without passing through a liquid phase. The advantages of lyophilization include product stability in a dry state, removal of water without excessive heating, and enhanced stability of a dry powder.
Get a glance at the market contribution of various segments Request a PDF Sample
The lyophilized powder segment was valued at USD 695.57 million in 2017 and continued to grow by 2021. Various vendors, such as Intas Pharmaceuticals, offer lyophilization powder for cancer treatment. Trastuzumab lyophilized powder by Intas Pharmaceuticals is used in treating metastatic breast cancer, early breast cancer, and metastatic gastric cancer. The growing number of breast cancer cases is one of the driving the demand for lyophilized powder. This, in turn, will drive the growth of the segment during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Cancer is one of the most common chronic diseases in North America. According to the Centers for Disease Control and Prevention (CDC), breast cancer is one of the most common types of cancer among women in the US. The region has been witnessing constant R&D activities in the oncology sector to lower the overall cancer mortality rate and help increase the life expectancy and quality of life of cancer patients. Awareness initiatives promoting are also contributing to the growth of the market in the region. Such factors will will drive the growth of the regional doxorubicin market during the forecast period.
This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. The outbreak of COVID-19 negatively affected the growth of the doxorubicin market in 2020. Due to lockdown and travel restrictions, some private clinics were closed, which resulted in the decreased registration of cancer patients. However, in 2021, governments started vaccination programs and lifted lockdown and travel restrictions in this region. This, in turn, restored the demand for doxorubicin. Such factors will increase the demand for cancer treatment, which will drive the growth of the regional doxorubicin market during the forecast period.
The report forecasts market growth by revenue at global, regional, and country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The reports categorize the global doxorubicin market as a part of the pharmaceuticals market, which covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.
Doxorubicin Market Scope |
|
Report Coverage |
Details |
Page number |
157 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.07% |
Market growth 2023-2027 |
USD 469.97 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.45 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 47% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aurobindo Pharma Ltd., Baxter International Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Meiji Holdings Co. Ltd., Merck KGaA, Mitsui and Co. Ltd., Novartis AG, Pfizer Inc., Pharmagen CZ s.r.o, Sun Pharmaceutical Industries Ltd., Synbias Pharma AG, TTY Biopharm Co. Ltd., Zydus Lifesciences Ltd., S. G. Biopharm Pvt. Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Formulation
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.